Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts
Identifying miRNA in Biofluids to be Applied as Robust Biomarkers for Disease, Toxicology or Injury Studies – The case of Minimally Invasive Colorectal Cancer Detection
Peter Mouritzen, Exiqon, speaking at Genomics Research Europe 2012
Date Posted: Thursday, January 24, 2013
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
These new products offer a powerful alternative to existing siRNAs already on the market place.
Tuesday, May 26, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Awarded Global microRNA Research Tools Company of the Year
Company has been recognized as the recipient of the award in light of the excellence that Exiqon has exhibited in the microRNA research space.
Monday, July 08, 2013
Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
The Service Center Agreement allows Asuragen to provide real-time PCR services based on Exiqon’s miRCURY LNA™ Universal RT microRNA PCR products.
Tuesday, June 11, 2013
Exiqon Announces 2011 Grant Program for MicroRNA Research
Company announces the launch of 2011 global research grant program, open to researchers from academic and non-profit institutions.
Wednesday, February 02, 2011
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators.
Tuesday, December 01, 2009
Exiqon partners with MedTrust Online to Promote Molecular Oncology Diagnostic Services to Oncologists
Exiqon will provide a comprehensive suite of oncology molecular diagnostics services to MedTrust Online's Oncocentric oncology portal.
Wednesday, June 03, 2009
Exiqon Expands in US; Sales Headquarters Established
Establishing a US presence will liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia.
Thursday, September 14, 2006
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
What Drives Advanced Prostate Cancer?
Large international study finds 90% have anomaly that could influence treatment.
Slinky Lookalike “Hyperlens” Helps Us See Tiny Objects
The photonics advancement could improve early cancer detection, nanoelectronics manufacturing and scientists’ ability to observe single molecules.
Phages Transducing Antibiotic Resistance Detected In Chicken Meat
Study shows phages are able to transfer antimicrobial resistance to bacteria.
‘Measuring Stick’ Standard for Gene Sequencing Now Available from NIST
New reference material, NIST RM 8398, to “map” DNA for genetic testing.
Single-cell Analysis Hits its Stride
Advances in technology and computational analysis enable scale and affordability, paving the way for translational studies.
Freshly Squeezed Vaccines
Microfluidic cell-squeezing device opens new possibilities for cell-based vaccines.
It Runs in the Family
Distantly related viruses share a common machinery for replication.
Scientists Create Mice with a Major Genetic Cause of ALS and FTD
NIH-funded study provides new platform for testing treatments for several neurodegenerative disorders.
New Target for Treating Rheumatoid Arthritis
Many affected individuals still suffer with progressive joint damage, despite treatment. This study has discovered a new treatment target which could open a door to preventing this ongoing damage.
Shining A New Light On The Immune System
Scientists at the University of St Andrews have developed a revolutionary method of identifying cells of the immune system with “molecular fingerprints” which could pave the way for the rapid detection of conditions such as leukaemia and lymphoma from a small blood sample.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters